Clinical Research Projects
Explore the T1DCRN’s portfolio of cutting-edge type 1 diabetes clinical projects.
Current Clinical Research Projects
There is increasing evidence that the gut microbiota may play a role in the development of autoimmune diseases including type 1 diabetes. This study will test the safety and feasibility of a modified starch, that altered the gut environment and immune system preventing T1D in mice, in adults with T1D for the first time. This study will inform a larger clinical trial, potentially bringing a new treatment or preventative therapy to people with T1D or those at risk. Find out more.
Keeping blood glucose levels in a normal range is difficult and places an enormous burden on people living with T1D. This program is evaluating the use of “artificial pancreas” devices in children and adults, and looking at the potential benefits for blood glucose control and quality of life. Find out more.
The ENDIA study will follow pregnant women whose unborn baby will have an immediate relative with T1D. The babies and their mothers will be followed throughout pregnancy and the early years of life to look at exposure to potential environmental triggers for T1D. If we can understand exactly what in the environment is harmful or protective, we can develop strategies to prevent T1D. Find out more.
Damage to the back of the eye is a common complication of type 1 diabetes, and can lead to blindness. The Fenofibrate and Microvascular Events (FAME) 1 Eye Study is investigating whether fenofibrate, a drug that is used to lower cholesterol and blood fats, can slow or reverse eye damage and other complications in adults with type 1 diabetes. Find out more.
There is an urgent need to develop new treatments to arrest, reverse and prevent the development of kidney complications. This clinical trial is testing a novel antioxidant drug in people with T1D and early kidney disease, to see if it can improve kidney function. Find out more.
Everyday activities such as exercise and eating can cause unpredictable fluctuations in blood glucose levels. This program will look at how food and exercise impact blood glucose, so new guidelines for managing food and exercise with T1D can be developed. Find out more.
A major barrier to widespread use of islet transplantation to cure T1D is immune rejection of the transplanted islets. This program aims to develop novel drug-free strategies for islet transplantation to make this treatment more widely available for people living with T1D. Find out more.
The PLGS clinical trial is investigating a Predictive Low Glucose Suspend feature on insulin pumps. This study is evaluating a novel algorithm for hypoglycemia prediction, under test conditions of excess insulin and moderate intensity exercise, to determine if the response of insulin suspension is safe and effective. Find out more.
The international REMOVAL study aims to discover whether metformin, a commonly used type 2 diabetes drug, can slow or prevent the development of cardiovascular complications in type 1 diabetes. The Australian sub-study looks into the effects of metformin on the heart and blood vessels in the eyes and limbs, and on novel blood markers of artherosclerosis. Find out more.
T1D Game Changer
Photo: Hugh (age 3) was diagnosed with type 1 diabetes at the age of 16 months. He lives in New South Wales.